Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC) Meeting Abstract


Authors: Rugo, H. S.; Barry, W. T.; Moreno-Aspitia, A.; Lyss, A.; Huebner, L.; Mayer, E. L.; Naughton, M.; Layman, R. M.; Carey, L. A.; Somer, R. A.; Toppmeyer, D.; Velasco, M.; Perez, E. A.; Hudis, C. A.; Winer, E.
Abstract Title: Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
Meeting Title: 40th Annual San Antonio Breast Cancer Symposium (SABCS 2017)
Journal Title: Cancer Research
Volume: 78
Issue: 4 Suppl.
Meeting Dates: 2017 Dec 5-9
Meeting Location: San Antonio, TX
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2018-02-01
Language: English
ACCESSION: WOS:000425489400020
PROVIDER: wos
DOI: 10.1158/1538-7445.SABCS17-GS3-06
Notes: Meeting Abstract: GS3-06 -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Clifford Hudis
    904 Hudis